In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 0.01 a new company low.

Within Major Pharmaceutical Preparations industry 556 other companies have achieved higher Quick Ratio than Acer Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 4705 to 5105.

Explain Quick Ratio?
How much Cash & cash equivalents ACER�s has?
What are ACER�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACER Quick Ratio	(Sep 30 2023) Q3	(Jun 30 2023) Q2	(Mar 31 2023) Q1	(Dec 31 2022) Q4	(Sep 30 2022) Q3
Y / Y Current Liabilities Change	610.08 %	369.74 %	316.38 %	-34.9 %	-31.15 %
Y / Y Cash & cash equivalent Change	-90.68 %	-89.26 %	-69.33 %	-81.68 %	-54.93 %
Quick Ratio MRQ	0.01	0.04	0.17	0.12	0.73
ACER's Total Ranking	# 5105	# 4705	# 3480	# 3823	# 1826
Seq. Current Liabilities Change	42 %	14.28 %	100.51 %	118.21 %	-6.06 %
Seq. Cash & cash equivalent Change	-61.72 %	-75.65 %	173.91 %	-63.48 %	-55.92 %

Quick Ratio third quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 557
Healthcare Sector	# 1124
Overall Market	# 5105

Quick Ratio Statistics
High	Average	Low
21.43	3.47	0.01
(Sep 30 2018)		(Sep 30 2023)

Financial Statements
Acer Therapeutics Inc 's Current Liabilities	$ 62 Millions	Visit ACER's Balance sheet
Acer Therapeutics Inc 's Cash & cash equivalent	$ 1 Millions	Visit ACER's Balance sheet
Source of ACER's Sales		Visit ACER's Sales by Geography

Cumulative Acer Therapeutics Inc 's Quick Ratio

ACER's Quick Ratio for the trailling 12 Months

ACER Quick Ratio	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months
Y / Y Current Liabilities TTM Growth	188.52 %	81.49 %	17.36 %	-32.34 %	26.67 %
Y / Y Cash & cash equivalent TTM Growth	-80.03 %	-73.22 %	-57.65 %	-32.23 %	-6.18 %
Quick Ratio TTM	0.07	0.15	0.39	0.96	0.97
Total Ranking TTM	# 4069	# 3932	# 2911	# 3988	# 2810
Seq. Current Liabilities TTM Growth	48.58 %	45.65 %	62.76 %	-18.09 %	-6.54 %
Seq. Cash & cash equivalent TTM Growth	-34.75 %	-43.7 %	-32.79 %	-19.1 %	-12.51 %

Quick ratio ranking by company, industry and sector >> Back to ACER Financial Strength Comparisons >> Go to Compare ACER Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2023 to $61.67 millions, cumulative Quick Ratio decreased to 0.07 below the Acer Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 538 other companies have achieved higher Quick Ratio than Acer Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3932 to 4069.

Explain Quick Ratio?
How much Cash & cash equivalents ACER�s has?
What are ACER�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 539
Healthcare Sector	# 1090
Within the Market	# 4069

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.54	3.25	0.07
(Mar 31 2019)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2023 MRQ Cash & cash equivalent	Sep 30 2023 MRQ Current Liabilities
Athersys Inc	0.03	$ 1.020 Millions	$ 38.624 Millions
Emmaus Life Sciences Inc	0.02	$ 1.505 Millions	$ 60.917 Millions
Citius Oncology Inc	0.02	$ 0.027 Millions	$ 1.164 Millions
Hst Global Inc	0.02	$ 0.002 Millions	$ 0.093 Millions
One World Products Inc	0.02	$ 0.095 Millions	$ 4.513 Millions
Vaccinex Inc	0.02	$ 0.127 Millions	$ 6.195 Millions
Baudax Bio Inc	0.02	$ 0.363 Millions	$ 19.051 Millions
Regen Biopharma Inc	0.02	$ 0.121 Millions	$ 6.949 Millions
IMPACT BIOMEDICAL INC.	0.02	$ 0.201 Millions	$ 12.382 Millions
Cytodyn inc	0.02	$ 2.034 Millions	$ 129.053 Millions
Oncotelic Therapeutics Inc	0.02	$ 0.268 Millions	$ 17.111 Millions
Avenir Wellness Solutions Inc	0.01	$ 0.189 Millions	$ 12.789 Millions
Acer Therapeutics Inc	0.01	$ 0.595 Millions	$ 61.670 Millions
Kaya Holdings Inc	0.01	$ 0.060 Millions	$ 7.771 Millions
Axim Biotechnologies Inc	0.01	$ 0.032 Millions	$ 4.278 Millions
Orgenesis Inc	0.00	$ 0.055 Millions	$ 14.302 Millions
Scienture Holdings Inc	0.00	$ 0.034 Millions	$ 9.092 Millions
Novaccess Global Inc	0.00	$ 0.021 Millions	$ 5.889 Millions
Celularity Inc	0.00	$ 0.273 Millions	$ 84.632 Millions
REST EZ Inc.	0.00	$ 0.000 Millions	$ 0.042 Millions
Biostax Corp	0.00	$ 0.010 Millions	$ 4.212 Millions
REGENEREX PHARMA, INC.	0.00	$ 0.006 Millions	$ 2.808 Millions
Propanc Biopharma Inc	0.00	$ 0.007 Millions	$ 3.133 Millions
China Health Industries Holdings Inc	0.00	$ 0.012 Millions	$ 5.961 Millions
Aridis Pharmaceuticals Inc	0.00	$ 0.035 Millions	$ 17.482 Millions

Date modified: 2026-08-29T17:21:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.